AI assistant
BTC HEALTH LTD — Net Asset Value 2012
Mar 5, 2012
64575_rns_2012-03-05_048b3ca4-2b71-4174-83c9-6ff523741c94.pdf
Net Asset Value
Open in viewerOpens in your device viewer
==> picture [135 x 99] intentionally omitted <==
06 March 2012: Net Tangible Asset (NTA) Backing – February 2012
| 29 February 2012 | 29 February 2012 | Cost Price | Cost Price | Board Valuation1 | Market Valuation2 | |
|---|---|---|---|---|---|---|
| Company | ASX Code | Cost Price Cents per BTC share |
Current Value Cents per BTC share* |
Current Value Cents per BTC share* |
||
| LISTED SECURITIES 1 Neurodiscovery TOTAL LISTED SECURITIES UNLISTED SECURITIES 2 Biocomm 3 Generic Health 4 Sensear 5 XRT General Provision TOTAL UNLISTED SECURITIES Cash |
NDL | 1,500,000 $ 2.01c |
190,588 $ 0.26c |
211,765 $ 0.28c |
||
| 1,500,000 $ 2.01c |
190,588 $ 0.26c |
211,765 $ 0.28c |
||||
| 1,235,701 $ 1.66c 2,200,000 $ 2.95c 3,116,761 $ 4.18c 5,625,000 $ 7.54c 0.00c |
1,235,701 $ 1.66c 2,200,000 $ 2.95c 3,338,984 $ 4.48c - $ 0.00c 1,783,668 -$ -2.39c |
1,235,701 $ 1.66c 2,200,000 $ 2.95c 3,338,984 $ 4.48c - $ 0.00c 1,783,668 -$ -2.39c |
||||
| 12,177,463 $ 16.33c |
4,991,017 $ 6.69c |
4,991,017 $ 6.69c |
||||
| 707,473 $ 0.95c |
707,473 $ 0.95c |
707,473 $ 0.95c |
||||
| Tax Provision | - $ 0.00c |
- $ 0.00c |
- $ 0.00c |
|||
| TOTAL | 14,384,935 $ 19.29c |
5,889,078 $ 7.90c |
5,910,255 $ 7.93c |
1 Board Valuation as defined by BioTech Capital's Investment policy including provision for tax
2 Market Valuation removes any discounts on holding value and still includes provision for tax
| Neurodiscovery | ||
|---|---|---|
| VWAP price used was: | $0.0240 | |
| Discount factor to valuation: | 10% | |
| Discounted Price: | $0.022 | |
| Securities held: | 8,823,530 | |
| BioTech Capital issued capital: | ||
| Ordinary Shares | 74,554,108 |
Commentary
The above table reflects the current fair market valuation based on all information known as at month end.
Valuations
The above table provides investors with two valuation approaches for BioTech Capital Ltd (“BTC”). The “Board Valuation” column is based upon the investment policy of the Board and is broadly in line with industry standard practices. The “Market Valuation” approach removes any discounts applied to the listed securities contained within the portfolio and is provided purely for information purposes in an attempt to provide as much visibility to investors on the true underlying value of the portfolio as possible.
About BioTech Capital Ltd
BioTech Capital Ltd (“BTC”) is a listed, life-science focused private equity fund and currently has investments in a diverse group of Australian life-science companies. As a registered Pooled Development Fund (PDF), investors are generally exempt from tax on capital gains and income. Shareholders have approved a change in investment strategy whereby no new investments will be made and capital will be returned to shareholders as investments are realised. BTC is listed on the Australian Stock Exchange (Code: BTC). Additional information can be found at www.biotechcapital.com.au
Contact Information
Harry Karelis, Director, Biotech Capital Ltd, Ph: +61 413 056 328, E-mail: [email protected]
Biotech Capital Limited ABN 45 091 979 172 www.biotechcapital.com.au
1 Edmondson Crescent T +61 413 056 328 Karrinyup WA 6018 F +61 8 9327 1778 Australia